tiprankstipranks
Passage Bio (PASG)
NASDAQ:PASG
US Market
Want to see PASG full AI Analyst Report?

Passage Bio (PASG) Stock Forecast & Price Target

651 Followers
See the Price Targets and Ratings of:

PASG Analyst Ratings

Hold
5Ratings
Hold
1 Buy
4 Hold
0 Sell
Based on 5 analysts giving stock ratings to
Passage
Bio
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PASG Stock 12 Month Forecast

Average Price Target

$11.75
▲(0.69% Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Passage Bio in the last 3 months. The average price target is $11.75 with a high forecast of $23.00 and a low forecast of $7.00. The average price target represents a 0.69% change from the last price of $11.67.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","24":"$24","8.25":"$8.25","13.5":"$13.5","18.75":"$18.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$23.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,8.25,13.5,18.75,24],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.97,6.356923076923077,7.743846153846153,9.13076923076923,10.517692307692307,11.904615384615385,13.291538461538462,14.678461538461537,16.065384615384616,17.45230769230769,18.83923076923077,20.226153846153846,21.61307692307692,{"y":23,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.97,5.491538461538461,6.013076923076923,6.5346153846153845,7.056153846153846,7.577692307692307,8.099230769230768,8.62076923076923,9.142307692307693,9.663846153846153,10.185384615384613,10.706923076923076,11.228461538461538,{"y":11.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.97,5.126153846153846,5.282307692307692,5.438461538461539,5.594615384615384,5.75076923076923,5.906923076923077,6.063076923076923,6.219230769230769,6.375384615384615,6.531538461538462,6.687692307692307,6.843846153846154,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.7,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.72,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.6,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.74,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.11,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.13,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.68,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.22,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.8,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.07,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.78,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.85,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.97,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$23.00Average Price Target$11.75Lowest Price Target$7.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TD Cowen
Hold
Reiterated
05/12/26
Analysts' Top Healthcare Picks: Passage Bio (PASG), Esperion (ESPR)
Canaccord Genuity Analyst forecast on PASG
Canaccord Genuity
Canaccord Genuity
$23
Buy
97.09%
Upside
Reiterated
04/21/26
Canaccord Genuity Remains a Buy on Passage Bio (PASG)
Wedbush Analyst forecast on PASG
Wedbush
Wedbush
$32$8
Hold
-31.45%
Downside
Downgraded
04/21/26
Analysts Offer Insights on Healthcare Companies: Passage Bio (NASDAQ: PASG) and Immuneering (NASDAQ: IMRX)
Chardan Capital Analyst forecast on PASG
Chardan Capital
Chardan Capital
$7
Hold
-40.02%
Downside
Downgraded
04/20/26
Analysts Conflicted on These Healthcare Names: Passage Bio (NASDAQ: PASG) and Omnicell (NASDAQ: OMCL)
Lucid Capital Analyst forecast on PASG
Lucid Capital
Lucid Capital
$68$9
Hold
-22.88%
Downside
Downgraded
04/20/26
Passage Bio downgraded to Neutral from Buy at Lucid CapitalPassage Bio downgraded to Neutral from Buy at Lucid Capital
Guggenheim
$40$10
Buy
-14.31%
Downside
Reiterated
08/14/25
Passage Bio (PASG) Receives a Buy from Guggenheim
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TD Cowen
Hold
Reiterated
05/12/26
Analysts' Top Healthcare Picks: Passage Bio (PASG), Esperion (ESPR)
Canaccord Genuity Analyst forecast on PASG
Canaccord Genuity
Canaccord Genuity
$23
Buy
97.09%
Upside
Reiterated
04/21/26
Canaccord Genuity Remains a Buy on Passage Bio (PASG)
Wedbush Analyst forecast on PASG
Wedbush
Wedbush
$32$8
Hold
-31.45%
Downside
Downgraded
04/21/26
Analysts Offer Insights on Healthcare Companies: Passage Bio (NASDAQ: PASG) and Immuneering (NASDAQ: IMRX)
Chardan Capital Analyst forecast on PASG
Chardan Capital
Chardan Capital
$7
Hold
-40.02%
Downside
Downgraded
04/20/26
Analysts Conflicted on These Healthcare Names: Passage Bio (NASDAQ: PASG) and Omnicell (NASDAQ: OMCL)
Lucid Capital Analyst forecast on PASG
Lucid Capital
Lucid Capital
$68$9
Hold
-22.88%
Downside
Downgraded
04/20/26
Passage Bio downgraded to Neutral from Buy at Lucid CapitalPassage Bio downgraded to Neutral from Buy at Lucid Capital
Guggenheim
$40$10
Buy
-14.31%
Downside
Reiterated
08/14/25
Passage Bio (PASG) Receives a Buy from Guggenheim
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Passage Bio

3 Months
Whitney IjemCanaccord Genuity
Success Rate
6/14 ratings generated profit
43%
Average Return
-5.06%
Copying Whitney Ijem's trades and holding each position for 3 Months would result in 42.86% of your transactions generating a profit, with an average return of -5.06% per trade.
1 Year
Whitney IjemCanaccord Genuity
Success Rate
0/14 ratings generated profit
0%
Average Return
-42.96%
Copying Whitney Ijem's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -42.96% per trade.
2 Years
Success Rate
0/5 ratings generated profit
0%
Average Return
-51.92%
Copying Debjit Chattopadhyay's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -51.92% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PASG Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
4
3
7
8
6
Buy
1
0
1
1
1
Hold
0
0
0
7
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
5
3
8
16
15
In the current month, PASG has received 7 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. PASG average Analyst price target in the past 3 months is 11.75.
Each month's total comprises the sum of three months' worth of ratings.

PASG Financial Forecast

PASG Earnings Forecast

The previous quarter’s earnings for PASG were -$2.36.
The previous quarter’s earnings for PASG were -$2.36.
No data currently available

PASG Sales Forecast

The previous quarter’s earnings for PASG were $0.00.
The previous quarter’s earnings for PASG were $0.00.

PASG Stock Forecast FAQ

What is PASG’s average 12-month price target, according to analysts?
Based on analyst ratings, Passage Bio’s 12-month average price target is 11.75.
    What is PASG’s upside potential, based on the analysts’ average price target?
    Passage Bio has 0.69% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is PASG a Buy, Sell or Hold?
          Passage Bio has a consensus rating of Hold which is based on 1 buy ratings, 4 hold ratings and 0 sell ratings.
            What is Passage Bio’s price target?
            The average price target for Passage Bio is 11.75. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $23.00 ,the lowest forecast is $7.00. The average price target represents 0.69% Increase from the current price of $11.67.
              What do analysts say about Passage Bio?
              Passage Bio’s analyst rating consensus is a Hold. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of PASG?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.